Distribution of microRNA biomarker candidates in solid tissues and body fluids

ABSTRACT Small non-coding RNAs, especially microRNAs, are discussed as promising biomarkers for a substantial number of human pathologies. A broad understanding in which solid tissues, cell types or body fluids a microRNA is expressed helps also to understand and to improve the suitability of miRNAs as non- or minimally-invasive disease markers. We recently reported the Human miRNA Tissue Atlas (http://www.ccb.uni-saarland.de/tissueatlas) containing 105 miRNA profiles of 31 organs from 2 corpses. We subsequently added miRNA profiles measured by others and us using the same array technology as for the first version of the Human miRNA Tissue Atlas. The latter profiles stem from 163 solid organs including lung, prostate and gastric tissue, from 253 whole blood samples and 66 fractioned blood cell isolates, from body fluids including 72 serum samples, 278 plasma samples, 29 urine samples, and 16 saliva samples and from different collection and storage conditions. While most miRNAs are ubiquitous abundant in solid tissues and whole blood, we also identified miRNAs that are rather specific for tissues. Our web-based repository now hosting 982 full miRNomes all of which are measured by the same microarray technology. The knowledge of these variant abundances of miRNAs in solid tissues, in whole blood and in other body fluids is essential to judge the value of miRNAs as biomarker.

[1]  J. Mariani,et al.  The transcardiac gradient of cardio‐microRNAs in the failing heart , 2016, European journal of heart failure.

[2]  Xin Li,et al.  Decreased expression of microRNA-320a promotes proliferation and invasion of non-small cell lung cancer cells by increasing VDAC1 expression , 2016, Oncotarget.

[3]  Yu Yang,et al.  MicroRNA-320a promotes 5-FU resistance in human pancreatic cancer cells , 2016, Scientific Reports.

[4]  Y. Kakimoto,et al.  MicroRNA deep sequencing reveals chamber-specific miR-208 family expression patterns in the human heart. , 2016, International journal of cardiology.

[5]  R. Gambari,et al.  Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: New trends in the development of miRNA therapeutic strategies in oncology (Review) , 2016, International journal of oncology.

[6]  A. Orekhov,et al.  Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). , 2016, Journal of molecular and cellular cardiology.

[7]  Ying Wang,et al.  MiR-320a inhibits gastric carcinoma by targeting activity in the FoxM1-P27KIP1 axis , 2016, Oncotarget.

[8]  Eckart Meese,et al.  Can circulating miRNAs live up to the promise of being minimal invasive biomarkers in clinical settings? , 2016, Wiley interdisciplinary reviews. RNA.

[9]  A. Keller,et al.  Distribution of miRNA expression across human tissues , 2016, Nucleic acids research.

[10]  Christina Backes,et al.  Bias in High-Throughput Analysis of miRNAs and Implications for Biomarker Studies. , 2016, Analytical chemistry.

[11]  Christina Backes,et al.  High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer , 2015, Oncotarget.

[12]  Christina Backes,et al.  Towards Clinical Applications of Blood-Borne miRNA Signatures: The Influence of the Anticoagulant EDTA on miRNA Abundance , 2015, PloS one.

[13]  S. Rome,et al.  Diagnostic Value of Cell-free Circulating MicroRNAs for Obesity and Type 2 Diabetes: A Meta-analysis. , 2015, Journal of molecular biomarkers & diagnosis.

[14]  P. Raggi,et al.  Utility of Select Plasma MicroRNA for Disease and Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis , 2015, The Journal of Rheumatology.

[15]  H. Bannasch,et al.  Identification of a blood-borne miRNA signature of synovial sarcoma , 2015, Molecular Cancer.

[16]  Hans-Peter Lenhof,et al.  Circulating serum miRNAs as potential biomarkers for nephroblastoma , 2015, Pediatric blood & cancer.

[17]  Terrence S. Furey,et al.  MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn's Disease and May Have Prognostic Utility , 2015, Inflammatory bowel diseases.

[18]  Christina Backes,et al.  Longitudinal study on circulating miRNAs in patients after lung cancer resection , 2015, Oncotarget.

[19]  A. Keller,et al.  The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases , 2014, Molecular Cancer.

[20]  A. Keller,et al.  The human miRNA repertoire of different blood compounds , 2014, BMC Genomics.

[21]  C. Sander,et al.  A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing , 2007, Cell.